APR 04, 2016 6:21 AM PDT

Dual-Action Nanoparticles Report Cancer Cell Death in Real Time

WRITTEN BY: Xuan Pham
How do doctors and cancer patients know if their chemotherapy or radiation treatments are working to kill the tumor? Quite often, it is a tense process of wait-and-see. But a new technique could allow doctors to monitor cancer death in real time – an astonishing feat compared to the weeks and months of waiting for conventional treatments.
 
Nanoparticles target cancer cells and report back cell death

 Researchers at the Brigham and Women's Hospital (BWH) developed a method of tagging cancer cells as they die. This approach reportedly allows doctors to know the response of anticancer therapies within mere eight hours post treatments. And the technique holds promise for other chemotherapies and immunotherapies often used in cancer treatments. 

Their innovation rests on dual-action nanoparticles that deliver the drugs and report back the efficacy of the drugs in real time. The research team, led by Shiladitya Sengupta, leveraged the knowledge that specific caspase proteins are released when cells die. Thus, the nanoparticles has a ‘reporter element’ that glows green when they detect the presence of caspases after tumor cell deaths. The green fluorescent signals allow doctors to visualize treatment efficacy within hours after treatment and determine whether a tumor is resistant or susceptible to the drug.
 
"Using this approach, the cells light up the moment a cancer drug starts working. We can determine if a cancer therapy is effective within hours of treatment," said co-senior author Shiladitya Sengupta. "Our long-term goal is to find a way to monitor outcomes very early so that we don't give a chemotherapy drug to patients who are not responding to it."
 
To test the reporter system, the researchers filled the nanoparticles with paclitaxel, a common anticancer drug, in a pre-clinical model of prostate cancer. In parallel, they tested an immunotherapy agent against melanoma. Prostate tumors sensitive to paclitaxel had about 400 percent more fluorescent signals, as compared to paclitaxel-resistant tumors. Similarly, fluorescent signals were also significantly enhanced in drug-sensitive melanomas.
 
The experiments demonstrate that the dual-action nanoparticles can inform clinicians on the sensitivity state of tumors, thus allowing doctors to modify treatment plans accordingly sooner rather than later. According to the team, this is the first time that the anticancer actions of the nanoparticles have been captured in real time, in live organisms.
 
"We've demonstrated that this technique can help us directly visualize and measure the responsiveness of tumors to both types of drugs," said co-senior author Ashish Kulkarni. "Current techniques, which rely on measurements of the size or metabolic state of the tumor, are sometimes unable to detect the effectiveness of an immunotherapeutic agent as the volume of the tumor may actually increase as immune cells begin to flood in to attack the tumor. Reporter nanoparticles, however, can give us an accurate read out of whether or not cancer cells are dying."

Additional source: BWH press release
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
MAY 06, 2020
Cancer
MAY 06, 2020
Olanzapine useful for cancer patients managing nausea unrelated to chemo
A study published last week in JAMA Oncology reports that a generic drug called Olanzapine could be useful for cancer pa ...
MAY 14, 2020
Clinical & Molecular DX
MAY 14, 2020
New Tech Has Its AI on Brain Tumors
  A collaboration across 29 research and healthcare agencies is putting together the world’s largest brain tu ...
MAY 14, 2020
Drug Discovery & Development
MAY 14, 2020
Therapeutic for Gastrointestinal Tumors
The FDA has approved ripretinib (Qinlock) which is the first drug for fourth-line treatment of advanced gastrointestinal ...
JUN 14, 2020
Chemistry & Physics
JUN 14, 2020
Why Are There So Few Black People in STEM?
On June 10th, 2020, thousands of STEM scientists and organizations around the world went on strike to protest systemic r ...
JUN 17, 2020
Cancer
JUN 17, 2020
New test for high-grade serous ovarian cancer
Research published in Clinical Cancer Research describes a new test that is more effective at diagnosing ovarian cancer. ...
JUL 03, 2020
Cancer
JUL 03, 2020
Using Machine Learning to Further Classify Triple-Negative Breast Cancer
One of the challenges of facing cancer researchers is coming up with a clearly defined classification system. Cancer is ...
Loading Comments...